This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (42)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Grant W. Carlson, MD; Douglas R. Murray, MD; Robert Greenlee, MPH; Naomi Alazraki, MD; Cynthia Fry-Spray, PA; Rufus Poole, BS; Michel Blais, BS; Andrea Hestley, BA; John Vansant, MD

Arch Otolaryngol Head Neck Surg. 2000;126:433-437.

Background  The sentinel lymph node (SLN) biopsy is revolutionizing the surgical management of primary malignant melanoma. It allows accurate nodal staging, and targets patients who may benefit from regional lymphadenectomy and systemic therapy; however, its use in the management of head and neck melanoma has not been widely accepted.

Methods  A retrospective review of patients treated for clinical stages I and II malignant melanoma of the head and neck with dynamic lymphoscintigraphy and gamma probe–guided SLN biopsy.

Results  Fifty-eight patients (47 male and 11 female) were identified. Primary melanoma sites included the scalp (21), ear (8), face (13), neck (15), and eyelid (1). Primary tumor staging was T2 (11), T3 (24), and T4 (23). Dynamic lymphoscintigraphy visualized SLNs in 57 patients (98.3%). In 43 cases (75%) a single draining nodal basin was identified, and in 14 cases there were multiple draining nodal basins. Sentinel lymph nodes were successfully identified in 72 (96%) of 75 nodal basins. Positive SLNs were identified in 10 patients (17.5%). Sentinal lymph node positivity by tumor staging was T3, 16.7% and T4, 27.3%. Completion lymphadenectomy revealed residual disease in 3 patients (30%). Relapse occurred in 10 (21.3%) of the 47 patients with negative SLN biopsy results and 7 (70%) of those with positive results.

Conclusions  Gamma probe–guided SLN localization in the head and neck region was successful in 96% of draining nodal basins. It can target regional lymphadenectomy in patients who may benefit from regional nodal dissection.

From Emory University School of Medicine, Atlanta, Ga.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sentinel node identification in clinical stage Ia non-small cell lung cancer by a combined single photon emission computed tomography/computed tomography system
Nomori et al.
J. Thorac. Cardiovasc. Surg. 2007;134:182-187.
ABSTRACT | FULL TEXT  

Patterns of Drainage and Recurrence Following Sentinel Lymph Node Biopsy for Cutaneous Melanoma of the Head and Neck
Fincher et al.
Arch Otolaryngol Head Neck Surg 2004;130:844-848.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy for Head and Neck Melanomas
Chao et al.
Ann. Surg. Oncol. 2003;10:21-26.
ABSTRACT | FULL TEXT  

Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma
Schmalbach et al.
Arch Otolaryngol Head Neck Surg 2003;129:61-65.
ABSTRACT | FULL TEXT  

The Definition of the Sentinel Lymph Node in Melanoma Based on Radioactive Counts
Carlson et al.
Ann. Surg. Oncol. 2002;9:929-933.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanomas
Patel et al.
Arch Otolaryngol Head Neck Surg 2002;128:285-291.
ABSTRACT | FULL TEXT  

Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma
Dubois et al.
Arch Dermatol 2001;137:1217-1224.
ABSTRACT | FULL TEXT